Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
PLoS One ; 7(11): e49513, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23185347

RESUMEN

KU-55933 is a specific inhibitor of the kinase activity of the protein encoded by Ataxia telangiectasia mutated (ATM), an important tumor suppressor gene with key roles in DNA repair. Unexpectedly for an inhibitor of a tumor suppressor gene, KU-55933 reduces proliferation. In view of prior preliminary evidence suggesting defective mitochondrial function in cells of patients with Ataxia Telangiectasia (AT), we examined energy metabolism of cells treated with KU-55933. The compound increased AMPK activation, glucose uptake and lactate production while reducing mitochondrial membrane potential and coupled respiration. The stimulation of glycolysis by KU-55933 did not fully compensate for the reduction in mitochondrial functions, leading to decreased cellular ATP levels and energy stress. These actions are similar to those previously described for the biguanide metformin, a partial inhibitor of respiratory complex I. Both compounds decreased mitochondrial coupled respiration and reduced cellular concentrations of fumarate, malate, citrate, and alpha-ketogluterate. Succinate levels were increased by KU-55933 levels and decreased by metformin, indicating that the effects of ATM inhibition and metformin are not identical. These observations suggest a role for ATM in mitochondrial function and show that both KU-55933 and metformin perturb the TCA cycle as well as oxidative phosphorylation.


Asunto(s)
Antineoplásicos/farmacología , Metformina/metabolismo , Morfolinas/farmacología , Pironas/farmacología , Proteínas de la Ataxia Telangiectasia Mutada , Proteínas de Ciclo Celular/metabolismo , Línea Celular Tumoral , Proliferación Celular , Ácido Cítrico/química , Ciclo del Ácido Cítrico , Proteínas de Unión al ADN/metabolismo , Fumaratos/química , Células HeLa , Células Hep G2 , Humanos , Hipoglucemiantes/farmacología , Ácidos Cetoglutáricos/química , Malatos/química , Potencial de la Membrana Mitocondrial , Metformina/farmacología , Consumo de Oxígeno , Fosforilación , Proteínas Serina-Treonina Quinasas/metabolismo , Ácido Succínico/química , Proteínas Supresoras de Tumor/metabolismo
2.
Cancer Res ; 72(23): 6257-67, 2012 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-23041548

RESUMEN

Epidemiologic and experimental data have led to increased interest in possible roles of biguanides in cancer prevention and/or treatment. Prior studies suggest that the primary action of metformin is inhibition of oxidative phosphorylation, resulting in reduced mitochondrial ATP production and activation of AMPK. In vitro, this may lead to AMPK-dependent growth inhibition if AMPK and its effector pathways are intact or to an energetic crisis if these are defective. We now show that the effect of exposure of several transformed cell lines to metformin varies with carbon source: in the presence of glutamine and absence of glucose, a 75% decrease in cellular ATP and an 80% decrease in cell number is typical; in contrast, when glucose is present, metformin exposure leads to increased glycolysis, with only a modest reduction in ATP level and cell number. Overexpression of myc was associated with sensitization to the antiproliferative effects of metformin, consistent with myc involvement in "glutamine addiction". Our results reveal previously unrecognized factors that influence metformin sensitivity and suggest that metformin-induced increase in glycolysis attenuates the antiproliferative effects of the compound.


Asunto(s)
Carbono/metabolismo , Neoplasias del Colon/tratamiento farmacológico , Metformina/farmacología , Proteínas Proto-Oncogénicas c-myc/biosíntesis , Adenosina Trifosfato/metabolismo , Animales , Apoptosis , Procesos de Crecimiento Celular/efectos de los fármacos , Línea Celular Tumoral , Neoplasias del Colon/genética , Neoplasias del Colon/metabolismo , Neoplasias del Colon/patología , Glucosa/metabolismo , Glucosa/farmacología , Glutamina/metabolismo , Glutamina/farmacología , Hipoglucemiantes/farmacología , Ratones , Ratones Endogámicos C57BL , Fosforilación , Proteínas Proto-Oncogénicas c-myc/genética , Proteínas Proto-Oncogénicas c-myc/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...